TREATMENT STRATEGY FOR NSAID GASTROPATHY IN OSTEOARTHRITIS: A NEW APPROACH IN THERAPY

Saidov Shavkat Baxromovich; Xamrabaeva Feruza Ibragimovna

doi:10.5281/zenodo.10822451

TREATMENT STRATEGY FOR NSAID GASTROPATHY IN OSTEOARTHRITIS: A NEW APPROACH IN THERAPY

15.03.2024 International Scientific Journal "Science and Innovation". Series D. Volume 3 Issue 3

Saidov Shavkat Baxromovich, Xamrabaeva Feruza Ibragimovna

Abstract. This article reviews the treatment strategy for nonsteroidal anti-inflammatory drugs (NSAID) gastropathy in patients with osteoarthritis, presenting a new approach in the therapy of this condition. The authors discuss recent research and clinical data related to the use of drug combinations, including selective NSAIDs and proton pump inhibitors, as well as the role of zinc in improving treatment efficacy and reducing the risk of complications.

Keywords: osteoarthritis/osteoarthritis nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase (COX), NSAIDs-gastropathy, gastric mucosa, proton pump inhibitors, esomeprazole, zinc

References:

1. Abdulla A., Adams N., Bone M. et al. Guidance on the management of pain in older people. Age Ageing. 2013;42(Suppl 1):i1–57. 2. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Am J Gastroenterol. 2010 Dec;105(12):2533-49. 3. Allenyzx K.D., Coffmanyk C.J., Golightlyy Y.M. et al. Daily pain variations among patients with hand, hip, and knee osteoarthritis. Osteoarthritis and Cartilage. 2009;17:1275–1282. DOI: 10.1016/j.joca.2009.03.021. 4. Angel Lanas, Maarten Boers, Javier Nuevo. Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Ann Rheum Dis 2015; 74:675–681. 5. Atchison J.W., Herndon C.M., Rusie E. NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety. J Manag Care Pharm. 2013;19(9 Suppl A):S3–19. 6. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a pro-ton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a doubleblind, randomised trial. Lancet. 2007 May 12;369(9573):1621-6. doi: 10.1016/S0140-6736(07)60749-1. 7. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatology International. 2012;32(6):1491-1502. doi:10.1007/s00296-011-2263-6. 8. Epidemiology of Osteoarthritis: Literature Update. Current Opinion in Rheumatology. 2018;30(2):160–167. 9. GI Leontiadis, A Sreedharan, S Dorward, P Barton, B Delaney, CW Howden, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding // Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. doi: 10.3310/hta11510. 10. Goldstein J., Ingen H., Fort J.G. Nonspecific NSAIDs are associated with a higher incidence of upper gastrointestinal endoscopic ulcers than COX-2 specific inhibitors, regardless of age // Abstract book. Selected abstracts on celecoxib presented at the Annual European Congress of Rheumatology (EULAR), 2003. 11. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104:728 – 738. 12. Musumeci G., Aiello F.C., Szychlinska M.A. et al. Osteoarthritis in the XXIst Century: Risk Factors and Behaviours that Influence Disease Onset and Progression. International Journal of Molecular Sciences. 2015;16(3):6093–6112. DOI: 10.3390/ijms16036093. 13. Rostom A, Moayyedi P, Hunt R. Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks [2008]. Aliment Pharmacol Ther. 2009 Mar 1;29(5):481-96. 14. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcer by esomeprazole in at-risk patients using non-selective NSAIDs or COX-2 inhibitor. Am J Gastroenterol. 2006 Apr;101(4):701-10. doi: 10.1111/j.1572-0241.2006.00499.x Epub 2006 Feb 22. 15. Skrovanek S. et al. // World J. Gastrointest. Pathophysiol. – 2014. – Vol.15, N4. – Р.496–513. 16. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: Importance of cyclooxygenase inhibition and gastric hypermotility. World Journal of Gastroenterology: WJG. 2012; 18 (18): 2147–2160. 17. Van Tunen J.A.C., Peat G., Bricca A. et al. Association of osteoarthritis risk factors with knee and hip pain in a population-based sample of 29–59 year olds in Denmark: a cross-sectional analysis. BMC Musculoskelet Disorders. 2018;19:300. DOI: 10.1186/s12891-018-2183-7. 18. Vandraas K.F., Spigset O., Mahic M., Slordal L. Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. Eur J Clin Pharmacol. 2010;66:823–829. 19. Wongrakpanich S., Wongrakpanich A., Melhado K., Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging and Disease. 2018;9(1):143–150. 20. Балукова Е.В. НПВП-индуцированная гастропатия: от понимания механизмов развития к разработке стратегии профилактики и лечения // РМЖ. 2017. Т. 25. № 10. С. 697-702. 21. Дроздов В.Н., Ших Е.В., Лазарева Н.Б. Возможности снижения риска НПВП-гастропатии у больных остеоартритом. РМЖ. 2019;12:74-78. 22. Искаков Б.С., Кулембаева А.Б., Есиркепова Г.С. НПВП-индуцированные гастропатии в ревматологической практике: современные вопросы диагностики и лечения // Vestnik KazNMU. -2018 - №2. - С. 486-491. 23. Каратеев А.Е., Насонов Е.Л., Корешков ГГ. НПВП-индуцированная диспепсия: распространенность и возможность медикаментозной коррекции // Научно-практическая ревматол. 2003. № 5. С. 76-78. 24. Клименко А.А., Шостак Н.А. НПВП-гастропатия: вопросы диагностики и лечения // Лечебное дело. №3. - 2005. - С. 74-82. 25. Лаврова А.Е. Цинк и процессы перекисного окисления липидов у детей с хроническим гастродуоденитом на фоне пищевой аллергии // Детская гастроэнтерология: настоящее и будущее: материалы VII конгресса педиатров России. М., 2002. С. 157. 26. Марушко Ю.В., Асонов А.О. // Журн. Гродн. гос. мед. ун-та. – 2013. – №4. – С.87–90. 27. Минушкин О.Н. Тактика ведения больных с сочетанной патологией суставов и верхних отделов желудочно-кишечного тракта // Научно-практическая ревматология 2003; №4; 64-67. 28. Наумова О.В. Факторы риска формирования сочетанной НПВП ассоциированной гастро и гепатопатии у больных остеоартрозом и оценка эффективности профилактической противорецидивной терапии // Современные проблемы науки и образования. – 2017. – № 1. ; URL: https://science-education.ru/ru/article/view?id=26126 (дата обращения: 01.03.2024). 29. Подобед В.М. Цинк Карнозин: новая формула гастропротекции и восполнения дефицита цинка // Медицинские новости. – 2015. – №2. – С. 17–20. 30. Саидов Ш.Б., Хамрабаева Ф.И. Исследование гастропатии, вызванной приемом НПВП: анализ научных исследований // O‘zbekiston Harbiy Tibbiyoti 2023; 4(4); 106-108.